Introduction: Ovarian serous carcinoma is an aggressive malignancy, often with metastases at presentation. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has been studied as a treatment option for intraperitoneal spread of ovarian cancer. Hyperthermic intrathoracic chemotherapy, the thoracic counterpart to hyperthermic intraperitoneal chemotherapy, is emerging as a treatment option for both primary and secondary pleural cancers but has not previously been reported for treatment of ovarian metastases. The use of minimally invasive thoracoscopic techniques, including robotic assistance, for intrathoracic chemotherapy is rare. We present a case report of a patient with pleural metastasis of ovarian serous carcinoma treated with cytoreductive surgery and intrathoracic chemotherapy.
INTRODUCTION
Ovarian carcinoma is an aggressive malignancy that is often diagnosed with metastasis at presentation. Approximately 140 000 women will die of ovarian cancer globally in 2014, and it is the fifth most common cause of death for women in the United States. 1, 2 The current standard treatment is complete cytoreductive surgery (CRS) followed by intravenous platinum-taxane chemotherapy alone or a combination of intravenous and intraperitoneal chemo-therapy. [3] [4] [5] In view of the peritoneal surface of ovarian cancer, there is growing interest in the use of hyperthermic intraperitoneal chemotherapy (HIPEC) for women with recurrent epithelial ovarian carcinoma after surgical cytoreduction. [5] [6] [7] Hyperthermic intrathoracic chemotherapy (ITH), the thoracic counterpart to HIPEC, is a developing treatment modality for both primary and secondary pleural cancers but has not previously been reported for the treatment of ovarian metastases.
Intracavitary chemotherapy 8 is advantageous over traditional intravenous chemotherapy administration in that an increased surface area of the tumor cells is exposed to cytotoxic agents with less systemic toxicity. Chemotherapeutic agents, however, can penetrate a depth of only a few millimeters. Therefore CRS is a prerequisite for intracavitary chemotherapy because maximum macroscopic tumor removal creates the optimal exposure to the cytotoxic agents. Finally, hyperthermia itself is known to be cytotoxic by causing impaired DNA repair, denaturation of proteins, and induction of apoptosis. 8 The cytotoxic effect of hyperthermia is dependent on the time of heat exposure to the tissues and time relation to other therapies in addition to temperature. Hyperthermia also increases cell membrane permeability, thus increasing drug uptake by tumor tissue. This synergism can occur at mild hyperthermic temperatures (39°C-41°C) with drugs such as cisplatinum and mitomycin C but has been observed to decrease at temperatures Ͼ 43°C. Small bowel heat toxicity has also been shown to increase with temperatures Ͼ 43°C. Moreover, ITH is limited to a maximum temperature of 43°C because of an increased risk of pulmonary edema above this temperature. 9 We present a patient with pleural metastasis of ovarian serous carcinoma treated with CRS and ITH by robotically assisted minimally invasive thoracoscopic techniques.
CASE REPORT
The patient is a 55-year-old woman who underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy with cytoreduction in July 2011 for ovarian cancer and was noted to have a right-sided pleural effusion on postoperative radiographs. A thoracentesis showed that the effusion contained malignant cells. The patient completed an intravenous adjuvant chemotherapy regimen in March 2012 and remained in remission until a follow-up positron emission tomography/computed tomography (CT) scan in November 2012 showed an isolated right-sided pleural metastasis ( Figure 1 ). She sought consultation at our institution, where she underwent a diagnostic laparoscopy 2 months later, which did not identify occult peritoneal disease. Because of a questionable history of platinum allergy, the patient was given 1 cycle of intravenous platinum as a test dose 3 weeks before a planned intrathoracic CRS and hyperthermic chemotherapy perfusion.
Procedure
The patient underwent right-sided video-assisted thoracoscopic surgery with robotic assistance, as well as partial pleurectomy with resection of pleural, diaphragmatic, mediastinal, and pericardiac metastatic nodules. She was intubated with a single-lumen endotracheal tube with a bronchial blocker under bronchoscopic guidance to achieve one-lung ventilation. A portal approach was used without an access incision, similar to our setup for roboticassisted lobectomy. This entailed 5 incisions: two 8-mm ports for robotic arms, a 5-mm thoracic grasper port, a The inflammatory adhesions were lysed, and examination of the pleura showed that although no significant pleural fluid or visceral pleural nodules were present, there were scattered parietal pleural nodules as expected. The largest lesion was 0.8 cm thick and 5 cm in diameter, was located in the posterior mid thorax adjacent to the head of the ribs, and was resected along with all other visible nodules (Figure 2) . Robotic assistance allowed for maximum mobility and angulation to reach the lesions on the pleural surface. Larger lesions were resected individually, whereas smaller lesions were resected with partial pleurectomy by use of monopolar and bipolar cautery. Tumor nodules in the pericardial fat were resected by sharp dissection with hemostasis achieved with robotic clips and bipolar cautery. All visible macroscopic disease was resected. The patient was then prepared for hyperthermic chemoperfusion after hemostasis was ensured.
Chemoperfusion
Two inflow catheters were placed in the right and left robotic arm trocar sites, with one cannula just above the diaphragm and the other more anterior within the thorax positioned more cephalad. A 32F channel drain acting as the drainage cannula was placed through the camera port site, and the remainder of the working port sites were closed with sutures. The cannulas were connected to the Thermachem perfusion device circuit (Eight Medical, St. Paul, Minnesota). The reservoir had been preheated with Ringer lactate solution, which was used to fill the thorax. While the cisplatinum chemoperfusate was being prepared, the anesthesiologist administered 1503 mg (910 mg/m 2 ) of amifostine intravenously over a 15-minute period for renal protection. 10 ITH was performed with 330 mg (200 mg/m 2 ) of cisplatinum diluted with normal saline solution with flow rates between 1200 and 1700 mL/min for 60 minutes. Inflow temperatures were maintained between 41.3°C and 42.4°C, and outflow temperatures were maintained at 41°C to 42°C. The patient's systemic temperature at the start of perfusion was 34.6°C. External cooling with cooling blankets and icepacks was used during the perfusion to control the core body temperature. After 60 minutes, the cisplatinum was drained and the thorax was flushed with 3 L of Ringer lactate solution. Sodium thiosulfate was then infused intravenously for additional renal protection, initially with a bolus of 7 g (4 g/m 2 ) over a 10-minute period, followed by 20 g (12 g/m 2 ) over the next 6 hours. 10 At the conclusion of the procedure, the patient's core body temperature was 36.5°C. Excellent urine output was maintained throughout the perfusion, and an OnQ catheter (I-FLOW, Lake Forest, California) for postoperative pain management was placed under direct thoracoscopic vision. A 28F angled chest tube was placed over the diaphragm, and the lung was reinflated (Figure 3) . All remaining incisions were closed with sutures, and the patient was extubated at the end of the case. She was transferred to the surgical intensive care unit for observation.
RESULTS
The pathologic samples showed metastatic poorly differentiated/high-grade adenocarcinoma consistent with the patient's known primary of ovarian serous carcinoma. The surgical procedure was uncomplicated, and the patient tolerated the procedure well. She was observed in the surgical intensive care unit for 1 day and was discharged home on postoperative day 3.
The serum creatinine level remained in the normal range at 0.7 mg/dL, and the serum cisplatinum level postoperatively was 1500 g/L without concern regarding toxicity. There was no evidence of recurrence by whole-body positron emission tomography/CT at 3 months after surgery (Figure 4) . A subsequent CT scan of the chest, abdomen, and pelvis obtained at 8 months showed no evidence of disease recurrence. At 10 months, the Karnofsky performance score was 100 with no clinical signs of recurrence.
DISCUSSION
Current research in the surgical management of ovarian cancer is focused on the added benefits of HIPEC. [5] [6] [7] Although ITH has been studied for the treatment of pleurabased cancers including mesothelioma and metastases from thymic carcinoma, there are no published reports of the use of ITH in cases of pleural metastases from ovarian carcinoma.
The minimally invasive approach minimizes morbidity and contributes to a decreased hospital length of stay and faster recovery time. The advantage of the robotic approach with regard to pleural metastasectomy lies in the articulation of the instruments, which allows access to more of the pleural surface that is often limited by the bony thoracic cage in traditional thoracoscopy. In addition, port-site incisions can be used as inflow and outflow tracts for perfusion. There is also less concern about leakage of chemotherapy through the smaller incisions.
We report the first case of robotic-assisted ITH to treat pleural metastasis of ovarian carcinoma and propose that ITH may be a viable treatment option for appropriately selected patients in the future. Larger trials will be necessary to establish the efficacy and safety of ITH for metastatic ovarian cancer and to determine whether there is any impact on recurrence or survival.
